The estimated Net Worth of Beth C Seidenberg is at least $88 Milhão dollars as of 15 April 2021. Beth Seidenberg owns over 18,127 units of Atara Biotherapeutics Inc stock worth over $73,169,675 and over the last 21 years he sold ATRA stock worth over $14,537,220. In addition, he makes $302,492 as Independent Director at Atara Biotherapeutics Inc.
Beth has made over 7 trades of the Atara Biotherapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 18,127 units of ATRA stock worth $912,151 on 15 April 2021.
The largest trade he's ever made was selling 388,584 units of Atara Biotherapeutics Inc stock on 10 February 2014 worth over $10,740,462. On average, Beth trades about 8,051 units every 78 days since 2003. As of 15 April 2021 he still owns at least 8,805,015 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Beth Seidenberg stock trades at the bottom of the page.
Dr. Beth C. Seidenberg M.D. serves as Independent Director of the Company since August 2012. Dr. Seidenberg is the managing director of Westlake Village BioPartners, a venture capital firm that focused on life sciences that she founded in September 2018. Dr. Seidenberg is also a General Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. Dr. Seidenberg was previously the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc., a biotechnology company. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, and Merck. Dr. Seidenberg received a B.S. from Barnard College and an M.D. from the University of Miami School of Medicine and completed her post-graduate training at The Johns Hopkins University, George Washington University and the National Institutes of Health. Dr. Seidenberg has served on the board of directors of Epizyme, Inc. since 2008 and Progyny, Inc since 2010. Dr. Seidenberg formerly served on the board of TESARO from 2011 to 2018, and on the board of ARMO BioScience from 2012 to 2018.
As the Independent Director of Atara Biotherapeutics Inc, the total compensation of Beth Seidenberg at Atara Biotherapeutics Inc is $302,492. There are 11 executives at Atara Biotherapeutics Inc getting paid more, with Pascal Touchon having the highest compensation of $6,637,310.
Beth Seidenberg is 63, he's been the Independent Director of Atara Biotherapeutics Inc since 2012. There are 1 older and 16 younger executives at Atara Biotherapeutics Inc. The oldest executive at Atara Biotherapeutics Inc is Roy Baynes, 65, who is the Independent Director.
Beth's mailing address filed with the SEC is C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK, NY, 10018.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier, eRonald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: